Lushang Freda Pharmaceutical Co (SHSE:600223) Inventory-to-Revenue : 0.59 (As of Mar. 2024)

---

Lushang Freda Pharmaceutical Co Inventory-to-Revenue Chart

---

Competitive Comparison of Lushang Freda Pharmaceutical Co's Inventory-to-Revenue

For the Real Estate - Development subindustry, Lushang Freda Pharmaceutical Co's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

---

Lushang Freda Pharmaceutical Co's Inventory-to-Revenue Distribution in the Real Estate Industry

For the Real Estate industry and Real Estate sector, Lushang Freda Pharmaceutical Co's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Lushang Freda Pharmaceutical Co's Inventory-to-Revenue falls into.

---

Lushang Freda Pharmaceutical Co Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Lushang Freda Pharmaceutical Co's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Lushang Freda Pharmaceutical Co's Inventory-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

---

Lushang Freda Pharmaceutical Co  (SHSE:600223) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Lushang Freda Pharmaceutical Co's Days Inventory for the three months ended in Mar. 2024 is calculated as:

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Lushang Freda Pharmaceutical Co's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

---

Lushang Freda Pharmaceutical Co Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Lushang Freda Pharmaceutical Co's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Total Inventories Revenue Days Inventory Cost of Goods Sold Inventory Turnover

---

Lushang Freda Pharmaceutical Co (SHSE:600223) Business Description

Executives

Li Hang	senior management
Yin Wei	Directors, senior managers
Shao Zhao Wei	senior management
Wang Zhong Wu	senior management
Dong Hong Lin	Director
Zhou Hong Bo	senior management
Li Lu	senior management
Liu Zeng Wei	senior management
Zhang Quan Li	senior management
Xu Tao	senior management
Ju Hai Bo	Director
Zhao Xi Liang	Director
Pi Xi Cai	Supervisors